公开(公告)号：US11452884B2

公开(公告)日：2022-09-27

申请号：US15876401

申请日：2018-01-22

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Eric J. Toone ,  David Gooden ,  Frederic A. Bourke, Jr. ,  Harold Walder

IPC: A61K31/37 ,  A61N5/06 ,  A61N5/10 ,  A61K39/39 ,  C07D493/04

Abstract: Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US20180169433A1

公开(公告)日：2018-06-21

申请号：US15876401

申请日：2018-01-22

Applicant: Immunolight, LLC ,  Duke University

Inventor： Eric J. Toone ,  David Gooden ,  Frederic A. Bourke, JR. ,  Harold Walder

IPC: A61N5/06 ,  A61K39/39 ,  C07D493/04

CPC classification number: A61N5/062 ,  A61K31/37 ,  A61K39/39 ,  A61N5/0601 ,  A61N5/0616 ,  A61N5/10 ,  A61N2005/0612 ,  A61N2005/063 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1098 ,  C07D493/04

Abstract: Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US20160331731A1

公开(公告)日：2016-11-17

申请号：US15220596

申请日：2016-07-27

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Wenle XIA ,  David Gooden ,  Erik J. Soderblom ,  Eric J. Toone ,  Neil L. Spector ,  Wayne F. Beyer, JR. ,  Harold Walder

IPC: A61K31/436 ,  A61K31/4709 ,  A61K41/00 ,  A61K45/06

CPC classification number: A61K31/436 ,  A61K31/37 ,  A61K31/4709 ,  A61K31/517 ,  A61K41/0066 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

公开(公告)号：US09439897B2

公开(公告)日：2016-09-13

申请号：US14603539

申请日：2015-01-23

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Wenle Xia ,  David Gooden ,  Erik J. Soderblom ,  Eric J. Toone ,  Neil L. Spector ,  Wayne F. Beyer, Jr. ,  Harold Walder

IPC: A61K31/517 ,  A61K31/4709 ,  A61K31/436 ,  A61K31/37 ,  A61K41/00

CPC classification number: A61K31/436 ,  A61K31/37 ,  A61K31/4709 ,  A61K31/517 ,  A61K41/0066 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

Abstract translation: 用于治疗受试者细胞增殖疾病或病症的方法，包括将缺乏DNA交联基序的补骨脂素衍生物施用于癌细胞，施用补骨脂素或其衍生物和拉帕替尼，或施用补骨脂素或其衍生物和神经胶质细胞 ，并且进一步施加起始辐射能量形成能量源。

公开(公告)号：US10647664B2

公开(公告)日：2020-05-12

申请号：US14912134

申请日：2014-08-18

Applicant: Duke University

Inventor： Pei Zhou ,  Eric J. Toone ,  Robert A. Nicholas

IPC: A61K31/5375 ,  A61K31/165 ,  C07C259/06 ,  C07C259/10 ,  C07D231/12 ,  C07D213/64 ,  C07D295/135 ,  C07D295/155 ,  C07C317/44

Abstract: Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1, X3, and X4 are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

公开(公告)号：US09908851B2

公开(公告)日：2018-03-06

申请号：US14912137

申请日：2014-08-18

Applicant: Duke University

Inventor： Pei Zhou ,  Eric J. Toone ,  Robert A. Nicholas

IPC: A61K31/445 ,  C07D211/08 ,  C07D211/06 ,  C07D211/14 ,  A61K31/455

CPC classification number: C07D211/06 ,  A61K31/455 ,  C07D211/14

Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

公开(公告)号：US20170349544A1

公开(公告)日：2017-12-07

申请号：US15681894

申请日：2017-08-21

Applicant: Duke University

Inventor： Pei Zhou ,  Eric J. Toone

IPC: C07D207/273 ,  C07C237/34 ,  C07D295/155 ,  C07D277/22 ,  C07D275/03 ,  C07D265/30 ,  C07D263/16 ,  C07D261/08 ,  C07D257/04 ,  C07D249/04 ,  C07D233/64 ,  C07D231/12 ,  C07D213/73 ,  C07D209/20 ,  C07D205/085 ,  C07C311/39 ,  C07C311/37 ,  C07C311/19 ,  C07C275/28 ,  C07C275/24 ,  C07C275/14 ,  C07C259/06 ,  C07D307/36 ,  C07D333/06

Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

公开(公告)号：US20160221934A1

公开(公告)日：2016-08-04

申请号：US14912134

申请日：2014-08-18

Applicant: DUKE UNIVERSITY

Inventor： Pei Zhou ,  Eric J. Toone ,  Robert A. Nicholas

IPC: C07C259/06 ,  C07D213/64 ,  C07D231/12

CPC classification number: C07C259/06 ,  A61K31/5375 ,  C07C317/44 ,  C07D213/64 ,  C07D231/12 ,  C07D295/135 ,  C07D295/155 ,  Y02A50/402 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481

Abstract: Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1, X3, and X4 are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

Abstract translation: 公开了式（I）和（II）的化合物及其药学上可接受的盐，其中R，R 1，R 2，R 3，R 21，R 22，R 23，R 34，R 37，R 33，R 39，D，Q， Y，X，X1，X3和X4在本文中定义。 这些化合物可用于治疗革兰氏阴性菌感染。

公开(公告)号：US20160200673A1

公开(公告)日：2016-07-14

申请号：US14912136

申请日：2014-08-18

Applicant: DUKE UNIVERSITY

Inventor： Pei Zhou ,  Eric J. Toone ,  Robert A. Nicholas

IPC: C07C259/06 ,  C07D333/20 ,  C07D403/04 ,  C07D405/04 ,  C07D231/12 ,  C07D401/10 ,  C07D213/64

CPC classification number: C07D213/64 ,  C07C259/06 ,  C07D231/12 ,  C07D249/06 ,  C07D295/088 ,  C07D295/135 ,  C07D333/20 ,  C07D333/24 ,  C07D333/28 ,  C07D333/38 ,  C07D401/10 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04

Abstract: Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, Y, Z, X, R12, R17, R18, R19, Y1, Z1, X1, and X2 are defined herein. These compounds are useful for treating Gram-negative bacteria infections, such as Neisseria gonorrhoeae bacterial infections.

Abstract translation: 公开了式（I）和（II）的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，Y，Z，X，R 12，R 17，R 18，R 19， 和X2在本文中定义。 这些化合物可用于治疗革兰氏阴性细菌感染，如淋病奈瑟菌细菌感染。

公开(公告)号：US20190169114A1

公开(公告)日：2019-06-06

申请号：US16270291

申请日：2019-02-07

Applicant: Duke University ,  The University of North Carolina at Chapel Hill

Inventor： Pei Zhou ,  Eric J. Toone ,  Robert A. Nicholas ,  Ramesh Gopalaswamy ,  Xiaofei Liang ,  Frank Navas, III

IPC: C07C259/06 ,  C07C259/18 ,  C07C317/18 ,  C07C311/06 ,  C07C317/44 ,  A61P31/04

Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.